Please login to the form below

Not currently logged in
Email:
Password:

Synthetic Biologics hires Michael Kaleko as scientific director

Co-founder of Advanced Vision Therapies joins US biotech developing synthetic DNA-based treatments

Synthetic Biologics, a US biotech specialised in developing synthetic DNA-based treatments, has appointed Dr Michael Kaleko as its new scientific director.

Kaleko, who has been a biotech consultant since 2010, has worked in gene therapy for over 20 years and previously co-founded eyecare specialist Advanced Vision Therapies in 2002, before serving as the company's president and chief scientific officer.

Prior to this he co-directed research at Genetic Therapy, a subsidiary of Novartis, where he developed multiple gene transfer and gene expression platform technologies for haemophilia, cancer, diabetes and ocular diseases.

"We are pleased to welcome Mike to the Synthetic Biologics' team,” said Jeffrey Riley, CEO and chair at Synthetic Biologics.

“We expect that Mike's significant accomplishments in the field of gene therapy will be valuable assets as we continue the work to build our portfolio of synthetic biologics and DNA-based human therapeutics."

20th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics